KPV dosage: reported doses and schedule
An alpha-MSH fragment studied for gut inflammation in animals, with no human dosing trial.
Also called: Lys-Pro-Val, Lysine-proline-valine, alpha-MSH(11-13), KPV acetate.
Anti-inflammatory and antimicrobial peptides · C-terminal alpha-MSH tripeptide with preclinical anti-inflammatory activity · Evidence: Animal studies only.
Typical reported dose: 150–300 mcg a day by mouth
- Oral pills, 150-300 mcg: 150-300 mcg per day reported; 600 mcg/day was only planned. daily; precise timing not reported, by mouth. Reported by users, occasional report. Studied in: Adults describing gut symptoms on a forum. (source)
- Reported 500 mcg daily: 500 mcg under the skin once daily. once daily, under the skin. Reported by users, occasional report. Studied in: One adult reporting gut-inflammation self-use. (source)
- Reported two-week steps: 250 mcg daily for 2 weeks., then 500 mcg daily for 2 weeks., then 1,000 mcg daily for 2 weeks. daily, as reported in the same discussion, under the skin. Reported by users, rare report. Studied in: One forum user describing use for MCAS-like symptoms. (source)
- Reported twice daily with BPC-157: 250 mcg KPV per injection, twice daily; also 250 mcg BPC-157 each time. twice daily, morning and evening, under the skin. Reported by users, rare report. Studied in: A secondhand report about an adult with SIBO symptoms. (source)
These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.
Related to KPV
- LL-37: A human defense peptide with mixed topical wound-trial results and no established injection regimen.
- BPC-157: An experimental repair peptide with mostly animal evidence and a few small human reports.
- GHK-Cu: A copper-binding skin peptide with small topical studies and untested systemic injections.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Concerns regarding the public health risks associated with unapproved peptide products, Therapeutic Goods Administration and Chief Medical Officer · Therapeutic Goods Administration · 2026
- Evaluation of KPV-related Bulk Drug Substances (KPV (free base) and KPV acetate) for Inclusion on the 503A Bulk Drug Substances List, FDA · 2026
- Federal Register: nonbinding draft HHS interim policy, October 30 2026, 2026
- HHS 503A peptide interim enforcement policy and conditions, October 30 2026, 2026
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee - 07/23/2026, FDA · FDA · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- MHRA Products | Home, MHRA · MHRA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- Ulcerative colitis, NHS · 2026
- Unapproved peptide product promoters and suppliers are put on notice, Therapeutic Goods Administration · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.